Lung cancer management in low and middle-income countries - current challenges and potential solutions

The field of thoracic oncology witnessed immense growth in the last two decades. From the development of effective lung cancer screening guidelines which aim for an early diagnosis of asymptomatic and non-metastatic lung cancers to the advent of immunotherapy and targetable tyrosine kinase inhibitors which aim to improve the quality of life and survival in metastatic lung cancer patients, several breakthroughs have been made. However, lung cancer remains the most common cause of cancer-related mortality despite all the advances, accounting for about 1.8 million deaths worldwide in 2020.¹ Several inequalities exist in managing lung cancer worldwide, which ultimately contribute to the disparities in its incidence and mortality burden. One commonly encountered reason for these inequalities is the socio-economic variations in the different parts of the world. The World Bank list of economies divides the countries into four sub-groups based on their Gross National Income (GNI) per capita- low income, lower-middle income, upper-middle income, and high income. Among the low- and middle-income countries, the age-standardized incidence and mortality are highest in Micronesia (36.4% and 34.9%, respectively) and Eastern Asian countries (34.4% and 28.1%, respectively), while its lowest in the Western-African region (2.2% and 2.1% respectively). Overall, about 60% of the world's lung cancer incidence is attributed to low- and middle-income countries, with the majority noted in the Asian continent.¹ Hence, recognizing the challenges faced by the patients and physicians in these countries is essential to improve the global outcomes of lung cancer.

Healthcare is divided into public and private sectors in most low- and middle-income countries. The government primarily sponsors public sector hospitals/universities, and they provide care to the patients at a low cost; however, most advanced diagnostics, procedures, and novel medications might not be readily available in these hospitals due to their cost limitations. The private sector hospitals tend to have an underlying for-profit motive. Though they have more access to the newer products, their use in public is limited to high-income or privately insured patients. Except for some upper-middle-income countries like China and Mexico, and a few lower-middle-income countries like Vietnam, most of the low-and middle-income regions do not have comprehensive nationally funded public health insurance programs that are able to cover the expensive testing and treatment required for lung cancer. Thus, patients must rely on private insurance or out-of-pocket payments which leads to financial toxicity.

Tobacco use is suspected to have killed 8 million people in 2019 and is the most common risk factor for lung cancer worldwide.^2,3 The tobacco cessation efforts by WHO (FCTC, NCD-GAP, MPOWER, and ENDS) have been instrumental in controlling the tobacco epidemic. The fourth edition of the WHO global report on the trends in the prevalence of tobacco use reported a global decline in tobacco use from 32.7% in 2000 to 22.3% in 2020.⁴ Lower-middle income groups had the highest drop in tobacco use (44% in 2000 to 24% in 2020), while the upper-middle income had the lowest and slowest drop (28% in 2000 to 24% in 2020). However, some of South-East Asian and Middle Eastern countries like Myanmar, Indonesia, and Lebanon still have a tobacco use prevalence as high as 50%.⁴ Primary and secondary smoking abstinence has been shown to be associated with improved survival outcomes.⁵ In the National Lung Cancer Screening trial, there was a 20% reduction in cancer-related mortality with 7-year smoking cessation.⁶ Despite the awareness and the evidence, there are about 49 countries that currently do not have a single national control measure, and a majority of them belong to low- and middle-income countries. In addition to cigarette use, other causes of nicotine exposure commonly encountered in low- and middle-income countries include second-hand tobacco smoke and the use of non-cigarette nicotine products like beedi, toombak.^2,7 These products are generally cheaper and cause higher nicotine exposure.⁸

The incidence of lung cancer in non-smokers is increasing globally. Majority of the Asian women with lung cancer are non-smokers. Some of the risk factors for lung cancer that have been proposed in this population are outdoor air pollution, environmental exposures (arsenic, asbestos), genetic factors, benign pulmonary conditions (pulmonary fibrosis) etc.⁹ In rural areas of India, indoor air pollutants like smoke from coal stoves and cooking oil have been attributed to lung cancer as well.¹⁰ Further case-control studies to help establish a definite causal relationship with these non-smoking factors is essential.

Wilson and Jungner laid down ten principles for disease screening in 1968, which are still used while deciding on screening recommendations for cancers.¹¹ Lung cancer biology and epidemiology make it a disease that would highly benefit from screening. The United States National Lung Screening Trial (NLST) and the Dutch-Belgian NEderlands Leuvens Screening Onderzoek¹² trial both demonstrated a significant reduction in lung cancer-related mortality with the use of annual low-dose CT screening in high-risk individuals.^13,14 United States Preventive Service Task Force (USPSTF) currently recommends LDCT for lung cancer screening in high-risk patients in the United States of America.¹⁵

The majority of the low- and middle-income countries with a high incidence of lung cancer, like India, Bangladesh, and Vietnam currently do not have screening guidelines established for lung cancer. In most low- and middle-income countries, nearly 80% of lung cancers are diagnosed as stage III or IV. Mortality in lung cancer is stage-dependent, with stage IV having the worst outcomes.¹⁶ Hence, early detection of lung cancer with the help of screening modalities can help decrease mortality. However, in practicality, several barriers exist for an effective implementation of lung cancer screening. A high prevalence of pulmonary infections like tuberculosis results in a high false positive rate.¹⁷ A positive screening test must be followed with several invasive and non-invasive interventions to ultimately lead to an accurate diagnosis. The imaging and interventional modalities needed for lung cancer screening can add to the already existing financial and infrastructure burden in the low- and middle-income healthcare systems.¹⁷

The goal of treatment for non-metastatic lung cancer is the cure, primarily obtained with surgery or with definitive radiation in patients who are not surgical candidates. Adjuvant systemic therapy is added to stage II and III lung cancers to improve the cure and survival rates.¹⁵

Surgery: Anatomic surgical resection (lobectomy and sometimes pneumonectomy) is the most common surgical procedure that is performed for an early-stage lung cancer with curative intent. The lung resection surgery can be performed via open thoracotomy, video-assisted thoracoscopic surgery (VATS) or robotic-assisted thoracoscopic surgery.^{18, 19} While VATS and RATS are associated with faster recovery and lesser post-operative complications, there is no difference in cancer related survival outcomes compared to open thoracotomy.²⁰ When surgical resection is indicated, open thoracotomy is the most commonly used approach in most low- and middle-income countries.²¹ VATS is being increasingly used in countries like Brazil and Vietnam.^{22, 23} RATS is less commonly available in most of these countries except for China, where robotic technology is rapidly advancing.^24,25 In countries with a high incidence of pulmonary infections, like India and Nepal, there is a concern for increased lung fibrosis and pleural adhesions making minimally invasive surgical resection less feasible.²⁶ The availability of skilled surgical oncologists or thoracic surgeons and post-operative rehabilitation resources differ widely throughout the world. The disparities in resource availability results in lower surgical resection rates; however, the overall post-operative outcomes are similar to high-income countries.²⁷

Radiotherapy (RT): For stages I and II non-small cell lung cancer (NSCLC), definitive RT is used in patients who are not surgical candidates. In inoperable stage III tumors, it is used along with chemotherapy (concurrent or sequential). In stage IV lung cancer, it is used for treatment of brain metastasis or oligo-progression or symptomatic disease. In limited-stage small-cell lung cancer (SCLC), prophylactic cranial radiation is given following concurrent chemoradiation to the chest.¹⁵ Hence, radiotherapy is a vital part of treatment for all stages of lung cancer management. The availability of radiotherapy equipment and techniques is variable in each country. In general, there is a paucity of RT availability in low- and middle-income countries. For example, India has radiotherapy equipment to serve only half of its current population.²⁸ Furthermore, only bigger cities within each country have established radiotherapy centers, making it difficult for the rural population to use them. Additionally, patients have a high wait time to receive RT due to limited availability. For instance, the average wait time for radiotherapy in Brazil is about 3-4 months.²² This can often result in the progression of the disease from a curative to non-curative stage or can cause the development of symptomatic metastasis intra- and extra-cranially.

Metastatic lung cancer is treated primarily with systemic agents to help improve quality of life, progression-free survival, and overall survival. The goal of treatment is palliative and not curative. Hence, it remains the most common cause of lung cancer-related mortality worldwide, with an average 5- year survival of 5-7% in the United States of America.²⁹ The systemic treatment in lung cancer underwent radical progress in the last decade with the dawn of immunotherapy and targetable tyrosine kinase inhibitors which are now readily available for patients in the high-income countries like the North American and European countries. However, most of the major clinical trials that led to the approval of these agents (especially immunotherapy trials) had minimal to no accrual from the low- and middle-income countries located in the Middle East, South Asia, and North and South African regions. This lack of inclusivity precipitates a lack of awareness, availability, and accessibility which along with the high economic burden results in lower utilization of these novel agents in low- and middle-income countries.

Tyrosine Kinase Inhibitors (TKI): Understanding the oncogenic drivers and targeting them with small molecule TKI revolutionized the management of non-small cell lung cancer (NSCLC). However, TKI use in most low- and middle-income countries is limited due to the lack of comprehensive molecular testing, lack of access to several TKIs, and the cost of the medication. It is thought that less than 50% of patients with NSCLC throughout the world receive molecular testing,³⁰ and the most commonly cited reasons for under testing are lack of availability/access and the cost. In Brazil, EGFR evaluation is estimated to be used in only half of the metastatic NSCLC due to the lack of advanced diagnostics.^22,31 In Nepal, the samples for comprehensive testing are sent to India and are generally associated with high expenses.²⁶ Like testing, there is also a stark difference in the availability of TKIs between high-income and low-income countries. Currently, several TKIs targeting EGRF, ALK, ROS, NTRK, BRAF, MET, RET, and most recently, KRAS G12C are approved and available in the USA and Europe. Out of all these mutations, EGFR is the most commonly encountered targetable mutation in NSCLC, with prevalence much higher in the East Asian population (EGFR mutation is noted in about 15% of NSCLC patients in the USA while it's frequency can be as high as 60% in East Asian countries).³² China is one of the few Asian countries in the upper-middle income group that actively participated in several TKI studies and currently has access to multiple TKIs targeting EGFR mutation, including Osimertinib.³³ However, the same cannot be said about the rest of South-East Asian countries. In Malaysia and Vietnam, Erlotinib and Gefitinib are the only available EGFR-TKIs in the public sector with reduced costs and national reimbursements. The rest of the EGFR TKIs must be fully paid for by the patients. The out-of-pocket monthly cost of Osimertinib is about 2000$ in Malaysia and 8000$ in India/Brazil.³⁴ A similar trend is seen with TKIs targeting mutations other than EGFR, with monthly costs ranging from 2000$ to 10,000$.²⁸ Hence, their use is limited as a second-line treatment for affluent patient populations in the tertiary healthcare systems.^23,35

Immunotherapy (IO): In the non-oncogene-addicted metastatic NSCLCs, an addition of immunotherapy significantly improved response rates and survival outcomes when compared with standard chemotherapy.^36‑39 Similarly, in small cell lung cancer (SCLC), an addition of immunotherapy to chemotherapy improved OS and PFS irrespective of PDL1 immunohistochemistry.^40,41 Immunotherapy is also responsible for producing a durable clinical benefit.^18,42 Currently, atezolizumab and durvalumab (PDL-1 inhibitors) are FDA approved for metastatic SCLC and, atezolizumab, pembrolizumab, cemiplimab (PD1 inhibitors) and nivolumab/ipilimumab (PD-1/CTLA4 inhibitor combination) are approved for metastatic NSCLC.¹⁵ Immunotherapy is also recommended in non-metastatic NSCLC. Durvalumab significantly improved survival in stage III NSCLC when given following chemoradiation.⁴³ Atezolizumab in the adjuvant setting improved disease-free survival for PDL-1 positive resectable stage II and IIIA NSCLC.⁴⁴ Additionally, neoadjuvant nivolumab in combination with chemotherapy has been shown to improve pathological complete response rates in resectable stage I to IIIA NSCLC.

Despite the ever-increasing evidence and indications for immunotherapy in high-income countries, their availability and utilization in low- and middle-income countries continue to remain low. Sudan does not have access to any immunotherapy agents or PDL-1 testing.⁴⁵ In South Africa, no checkpoint inhibitors are available for first-line treatment and Pembrolizumab is the only available IO in the second-line setting.²¹ In India, IOs are sold as branded medications and have an average cost of 2000-4000$ per vial, which significantly restricts their use (especially in the first-line setting).²⁸ Similar trends of restricting IO use to second-line setting are seen in most low- and middle-income countries in the Middle Eastern, North African (MENA), and Southeast Asian regions due to a financial burden. Owing to the lack of widespread global accessibility due to its cost, immunotherapy was not included in the essential medicine list by WHO.⁴⁶

Chemotherapy: Due to the cost and unavailability of most TKIs and IOs, platinum-based doublet chemotherapy remains the standard of care for first-line treatment of metastatic NSCLC and SCLC in low- and middle-income countries. In patients with NSCLC who have a driver mutation, every attempt is made to get cost-effective access to TKIs. In scenarios when the TKIs are unavailable or not affordable, chemotherapy is given in the first-line setting. There is not much discrepancy in the availability of most first- and second-line chemotherapy agents except for Pemetrexed which has limited availability in countries like South Africa and Malaysia.

In summary, every single aspect of lung cancer management, from epidemiologic risk mitigation to the availability of palliative treatment, is strongly influenced by the resources available in a country. These differences in the resources are often attributed to the financial burden of treatments, lack of accessibility and lack of awareness. Some of the potential solutions are:

1. Lung cancer prevention and screening: Implementing tobacco control policies like nicotine-replacement therapies, smoking-related cancer awareness campaigns and a nationwide ban on tobacco use in the public places can help decrease the prevalence of lung cancer. Use of plain packaging and graphic pictorial warnings on nicotine products has been shown to decrease their attractiveness especially to young population^47,48 and hence, wider implementation of these measures as suggested by WHO can help with smoking cessation. New Zealand recently announced national plans to ban tobacco products for anyone born after 2008. Similar age-based restrictions on nicotine use can target the youth and decrease the incidence of tobacco use. Hiking the prices of tobacco products can decrease their use as well. In addition to smoking cessation, starting a screening program can help reduce the long-term cancer-related mortality. Socio-economic burden is the biggest challenge in providing appropriate screening in the low- and middle-income countries, however, cultural concerns and fear of radiation exposure can also rarely lead to its underutilization.¹² Hence, investigating to understand the local population's outlook towards lung cancer screening and raising awareness utilizing national media can help deploy a successful screening program. Though these measures can increase the immediate cost of healthcare, focusing on lung cancer prevention and early detection can be cost-effective for a nation in the long run.

2. Clinical trials: There is an abundance of lung cancer patients in low- and middle-income countries who fit the general inclusion criteria noted in most lung cancer clinical trials. However, their inclusion in most trials is dismal. Through clinical trials, patients can get access to molecular testing and novel treatments like TKIs and CPIs at minimal to no cost.

3. National health insurance coverage: The population within each country is divided into multiple tiers based on individual income. Patients from high-income families can afford out-of-pocket payments or private insurance. On the other hand, patients from low-income households can rarely afford cancer treatments without almost bankrupting their families. Hence, having a nationally funded health insurance that works towards providing basic medical care including coverage to the well-acknowledged diagnostics and cancer treatments can result in uniform oncologic care. In addition to national provisions, state-based monetary help and hospital-based medical coverage for cancer patients as seen in certain states/hospitals of India can bridge the economic gap often seen in cancer care.

4. National cancer/disease registries: A national cancer registry can provide information on the most prevalent cancers and their mortality in each country. This can further help concentrate funds and resources on the cancer types that are adding the most social and economic burden on the country and its population. International investigators can also use this registry while considering clinical trial accrual.

5. National guidelines for management: Several low- and middle-income countries like Sudan, Nepal, and Georgia do not have national consensus guidelines for managing lung cancer and rely on National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) guidelines. NCCN has harmonized guidelines for countries in the Sub-Saharan Africa, the Middle East, North Africa, and the Caribbean regions.^49,50 However, there are no international guidelines that are focused on managing cancer for patients from South Asia, South-East Asia, Pacific Islands, and Latin America, which also have several low- and middle-income countries. Establishing national guidelines for managing lung cancer can help provide uniform care to patients within each country. Once these guidelines are made publicly available throughout the country, then, the insurance providers (both public and private ones) can be petitioned to provide sufficient coverage to the appropriate guideline-based treatments.

6. Teleoncology: Utilization of digital technologies like Telemedicine became essential during the pandemic era. In the low- and middle-income countries where the majority of the burden falls on the tertiary care hospitals, appropriate use of Teleoncology can reduce delay in oncologic care by triaging patients for screening, lab tests or invasive diagnostics.⁵¹ It can also help in patient counseling and surveillance.⁵²

7. Cost of the medication: The most encountered barrier to appropriate treatment in low- and middle-income countries is the cost of the treatment. Increasing the availability of bio-equivalent drugs can help decrease their expense. TKIs like gefitinib and alectinib are available as generic agents in India, which decreased the cost of the medication by almost half for the consumers. Doing the same for several TKIs and immunotherapy can help increase their affordability. Another important potential solution is the use of lower doses of therapeutic agents, especially immunotherapy to help mitigate their financial toxicity. A recent phase III trial from India showed improved survival in Head and Neck cancer with a combination of Nivolumab given at 6% of the recommended dose along with metronomic doses of chemotherapy drugs.⁵³ The possibility of ultra-low doses of anti-cancer drugs providing similar efficacy in Lung cancer needs to be further explored as it can help significantly decrease the total cost of the treatment.

None.

N/A

N/A

None

1. All authors: conception and design

2. All authors: data collection and assembly

3. All authors: data analysis, manuscript writing

All authors have approved the manuscript

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

2. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327-338. doi:10.3978/j.issn.2218-6751.2015.08.04

3. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2

4. Country Profiles. WHO Global Report on Trends in Prevalence of Tobacco Use 2000-2025, Fourth Edition. World Health Organization; 2021.

5. Moldovanu D, de Koning HJ, van der Aalst CM. Lung cancer screening and smoking cessation efforts. Transl Lung Cancer Res. 2021;10(2):1099-1109.doi:10.21037/tlcr-20-899

6. Tanner NT, Kanodra NM, Gebregziabher M, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193(5):534-541. doi:10.1164/rccm.201507-1420OC

7. Idris AM, Ibrahim YE, Warnakulasuriya KA, Cooper DJ, Johnson NW, Nilsen R. Toombak use and cigarette smoking in the Sudan: estimates of prevalence in the Nile state. Prev Med. 1998;27(4):597-603. doi:10.1006/pmed.1998.0331

8. Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Unchanging clinico-epidemiological profile of lung cancer in north India over three decades. Cancer Epidemiol. 2010;34(1):101-104. doi:10.1016/j.canep.2009.12.015

9. Swanton C, Hill W, Lim E, et al. LBA1 mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: towards molecular cancer prevention. Ann Oncol. 2022;33(suppl_7):S1413. doi:10.1016/j.annonc.2022.08.046

10. Noronha V, Dikshit R, Raut N, et al. Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer. 2012;49(1):74-81. doi:10.4103/0019-509X.98925

11. Wilson JMG, Jungner G, Organization WH. Principles and Practice of Screening for Disease.; 1968.

12. Jonnalagadda S, Bergamo C, Lin JJ, et al. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526-531. doi:10.1016/j.lungcan.2012.05.095

13. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120(4):868-874. doi:10.1002/ijc.22134

14. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873

15. Wood DE, Kazerooni EA, Aberle D, et al. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. J Natl Compr Canc Netw. 2022;20(7):754-764. doi:10.6004/jnccn.2022.0036

16. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. National Cancer Institute; 2014.

17. Shankar A, Saini D, Dubey A, et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Transl Lung Cancer Res. 2019;8(Suppl 1):S106-S121. doi:10.21037/tlcr.2019.03.03

18. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. doi:10.1016/S1470-2045(20)30539-8

19. Jiao W, Qiu T. The minimally invasive thoracic surgery for lung cancer: a voice from China. Indian J Cancer. 2015;51(Suppl 2):e2. doi:10.4103/0019-509X.151983

20. Chai T, Lin Y, Kang M, Lin J. Thoracotomy versus video-assisted thoracoscopic resection of lung cancer: a protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(10):e14646. doi:10.1097/MD.0000000000014646

21. van Eeden R, Tunmer M, Geldenhuys A, Nayler S, Rapoport BL. Lung cancer in South Africa. J Thorac Oncol. 2020;15(1):22-28. doi:10.1016/j.jtho.2019.06.032

22. Mathias C, Prado GF, Mascarenhas E, et al. Lung cancer in Brazil. J Thorac Oncol. 2020;15(2):170-175. doi:10.1016/j.jtho.2019.07.028

23. Tran HTT, Nguyen S, Nguyen KK, et al. Lung cancer in Vietnam. J Thorac Oncol. 2021;16(9):1443-1448. doi:10.1016/j.jtho.2021.06.002

24. O'Meara S. Medical robotics in China: the rise of technology in three charts. Nature. 2020;582(7813):S51-S52. doi:10.1038/d41586-020-01795-7

25. Sihoe ADL. Video-assisted thoracoscopic surgery as the gold standard for lung cancer surgery. Respirology. 2020;25(Suppl 2):49-60. doi:10.1111/resp.13920

26. Shilpakar R, Paudel BD, Sharma R, et al. Lung cancer in Nepal. J Thorac Oncol. 2022;17(1):22-29. doi:10.1016/j.jtho.2021.10.020

27.27. International Surgical Outcomes Study group. Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth. 2016;117(5):601-609. doi:10.1093/bja/aew316

28. Singh N, Agrawal S, Jiwnani S, et al. Lung cancer in India. J Thorac Oncol. 2021;16(8):1250-1266. doi:10.1016/j.jtho.2021.02.004

29. Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non–small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824-1832. doi:10.1001/jamaoncol.2021.4932

30. Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer. J Thorac Oncol. 2020;15(9):1434-1448. doi:10.1016/j.jtho.2020.05.002

31. Araujo LH, Baldotto C, Castro G Jr, et al. Lung cancer in Brazil. J Bras Pneumol. 2018;44(1):55-64. doi:10.1590/S1806-37562017000000135

32. Mitsudomi T. Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.Transl Lung Cancer Res. 2014;3(4):205-211. doi:10.3978/j.issn.2218-6751.2014.08.04

33. Luo YH, Chiu CH, Scott Kuo CH, et al. Lung cancer in Republic of China. J Thorac Oncol. 2021;16(4):519-527. doi:10.1016/j.jtho.2020.10.155

34. Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G Jr. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer. JAMA Oncol. 2018;4(8):1080-1084. doi:10.1001/jamaoncol.2018.1395

35. Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Lung cancer in Malaysia. J Thorac Oncol. 2020;15(3):317-323. doi:10.1016/j.jtho.2019.10.021

36. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005

37. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301. doi:10.1056/NEJMoa1716948

38. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865

39. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020-2031. doi:10.1056/NEJMoa1910231

40. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-2229. doi:10.1056/NEJMoa1809064

41. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630. doi:10.1200/JCO.20.01055

42. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881-895. doi:10.1016/j.annonc.2021.04.008

43. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. doi:10.1056/NEJMoa1809697

44. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5

45. Elhassan MMA, Mohamedani AA, Mohamed SAH, et al. Lung cancer in Sudan. J Thorac Oncol. 2022;17(4):489-498.

47. Thrasher JF, Rousu MC, Hammond D, Navarro A, Corrigan JR. Estimating the impact of pictorial health warnings and "plain" cigarette packaging: evidence from experimental auctions among adult smokers in the United States. Health Policy. 2011;102(1):41-48. doi:10.1371/journal.pone.0052206

48. White CM, Hammond D, Thrasher JF, Fong GT. The potential impact of plain packaging of cigarette products among Brazilian young women: an experimental study. BMC Public Health. 2012;12(1):737. doi:10.1186/1471-2458-12-737

49. Jazieh AR, Bamefleh H, Demirkazik A, et al. Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. J Natl Compr Canc Netw. 2010;8(Suppl 3):S-16-S-21. doi:10.6004/jnccn.2010.0118

50. Mutebi M, Adewole I, Orem J, et al. Toward optimization of cancer care in Sub-Saharan Africa: development of national comprehensive cancer network harmonized guidelines for Sub-Saharan Africa. JCO Glob Oncol. 2020;6(6):1412-1418. doi:10.1200/GO.20.00091

51. Kichloo A, Albosta M, Dettloff K, et al. Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA. Fam Med Com Health. 2020;8(3):e000530. doi:10.1136/fmch-2020-000530

52. Yadav K, Ginsburg O, Basu P, Mehrotra R. Telemedicine and cancer care in low- and middle-income countries during the SARS-CoV-2 pandemic. JCO Global Oncology. 2021;2021(7):1633-1638. doi:10.1200/GO.21.00249

53. Patil VM, Noronha V, Menon N, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023;41(2):222-232. doi:10.1200/JCO.22.01015